Nurix Therapeutics, Inc. (NRIX) News
Track canonical SquawkNews coverage tagged to NRIX, Nurix Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 13 indexed stories across 10 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
NRIX: Major Roche deal accelerates BTK degrader's global development and multi-billion dollar potential
A landmark Roche partnership expands the clinical and commercial reach of a BTK degrader, with pivotal trials underway and a strong safety profile supporting broad development in oncology and autoimmune diseases. Additio
NEWS | Sep 14, 2026, 06:49 PM UTC
M
NRIX expansion of BTK degrader backed by Roche partnership
NRIX said its BTK degrader is progressing in CLL, CSU and MS, while a Roche partnership expands indications and provides financial backing. The pipeline also includes STAT6 and IRAK4 degraders with multiple upcoming read
EQUITY | Sep 08, 2026, 08:01 PM UTC
L
Nurix Therapeutics management to participate in September investor conferences
Nurix Therapeutics said company management will participate in upcoming September investor conferences.
EQUITY | Sep 01, 2026, 12:07 PM UTC
L
NRIX - Nurix Therapeutics to Participate in Upcoming September Investor Conferences
NRIX - Nurix Therapeutics to Participate in Upcoming September Investor Conferences
EQUITY | Sep 01, 2026, 12:01 PM UTC
L
Nurix Therapeutics appoints Wes Burwell as chief human resources officer
Nurix Therapeutics says it has appointed Wes Burwell as chief human resources officer.
REGULATION | Aug 20, 2026, 11:00 AM UTC
H
Nurix Receives $10M Milestone Payment
Nurix gets $10M for starting a Phase 1 trial
EQUITY | Aug 04, 2026, 11:02 AM UTC
M
Nurix Enrolls First Patient in Phase 3 CLL Trial
Nurix starts Phase 3 trial for leukemia treatment
EQUITY | Aug 04, 2026, 05:00 AM UTC
L
NRIX Nurix Therapeutics announces hsr clearance of global collaboration with Roche to Co-develop and Co-commercialize potential best-in-clas
NRIX Nurix Therapeutics announces hsr clearance of global collaboration with Roche to Co-develop and Co-commercialize potential best-in-class btk degrader bexobrutideg across malignant hematology, immunology and neurolog
EQUITY | Jul 21, 2026, 08:01 PM UTC
H
Nurix Therapeutics price target raised to $34 from $32 at Truist
Truist analyst Gregory Renza raised the firm's price target on Nurix Therapeutics to $34 from $32 and keeps a Buy rating on the shares after its Q2 results. The company's earnings and the firm's follow-up call with the m
EQUITY | Jul 10, 2026, 12:42 PM UTC
L
Nurix Therapeutics reports Q2 EPS (81c), consensus (72c)
Reports Q2 revenue $9.04M, consensus $15.29M. "The second quarter of 2026 was a defining period for Nurix and the targeted protein degradation field," said Arthur Sands, president and chief executive officer of Nurix. "O
EQUITY | Jul 09, 2026, 08:08 PM UTC
H
Earnings Flash (NRIX) Nurix Therapeutics, Inc. Reports Q2 Revenue $9.0M, vs. FactSet Est of $15.3M
() -- Copyright © 2026. All rights reserved. does not provide investment advice. Unauthorized reproduction is strictly prohibited.
EARNINGS | Jul 09, 2026, 08:03 PM UTC
L
Top 3 Health Care Stocks That May Keep You Up At Night In June
As of June 30, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a
REGULATION | Jun 30, 2026, 12:55 PM UTC
M
12 Health Care Stocks Move
Multiple health care stocks are moving in Thursday's intraday session, with gainers including Atlantic International and SELLAS Life Sciences, and losers including Nano X Imaging and Passage Bio
EQUITY | Jun 25, 2026, 05:05 PM UTC